<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> therapy is associated with numerous cutaneous adverse effects </plain></SENT>
<SENT sid="1" pm="."><plain>While <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>-associated <z:e sem="disease" ids="C0699893" disease_type="Neoplastic Process" abbrv="">nonmelanoma skin cancers</z:e> are known to be associated with significant morbidity and occasional mortality, to date, <z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatomyositis</z:e>-like eruption has been considered a benign entity, other than its ability to mimic true <z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatomyositis</z:e> leading to inappropriate immunosuppression </plain></SENT>
<SENT sid="2" pm="."><plain>More recently, <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>-associated squamous <z:mpath ids='MPATH_589'>dysplasia</z:mpath> has been characterized as a premalignant precursor to <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>-associated <z:e sem="disease" ids="C0699893" disease_type="Neoplastic Process" abbrv="">nonmelanoma skin cancers</z:e> and shown to manifest abnormal p53 expression </plain></SENT>
<SENT sid="3" pm="."><plain>OBSERVATIONS: An elderly woman receiving <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> therapy for <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> developed a <z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatomyositis</z:e>-like eruption that was misdiagnosed as true <z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatomyositis</z:e>, leading to continuation of <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Years later she developed severe <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>-associated <z:e sem="disease" ids="C0699893" disease_type="Neoplastic Process" abbrv="">nonmelanoma skin cancers</z:e> resulting in discontinuation of <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>, poor control of her <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, and <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Re-evaluation with immunohistochemical analysis of tissue from her original <z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatomyositis</z:e>-like eruption revealed focal confluent nuclear expression of p53 along the lower layers of the epidermis, suggestive of a <z:e sem="disease" ids="C0032927" disease_type="Neoplastic Process" abbrv="">premalignant state</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: We suggest that <z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatomyositis</z:e>-like eruption and <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>-associated squamous <z:mpath ids='MPATH_589'>dysplasia</z:mpath> represent similar clinical manifestations of a common underlying <z:hpo ids='HP_0011010'>chronic</z:hpo> phototoxic process involving aberrant keratinocyte p53 expression mediated by <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>'s <z:chebi fb="0" ids="35221">antimetabolite</z:chebi> properties and UV radiation exposure </plain></SENT>
<SENT sid="7" pm="."><plain>Accordingly, we suggest that <z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatomyositis</z:e>-like eruption, previously considered a benign entity, may represent a premalignant precursor of <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>-associated <z:e sem="disease" ids="C0699893" disease_type="Neoplastic Process" abbrv="">nonmelanoma skin cancers</z:e> warranting discontinuation of <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> therapy </plain></SENT>
</text></document>